Clinical trials: Cancer, Bladder
Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma
Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma
This phase II trial studies how well atezolizumab when given with glycosylated recombinant human interleukin-7 (CYT107) works in treating patients with urothelial carcinoma that has spread to nearby tissue or lymph nodes (locally…
- Conditions
- Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma
- Trial name
- NCT03513952
- Testing
- Atezolizumab, Biopsy, Biospecimen Collection
- Where
- 9 sites in United States
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute (NCI)
Brain Metastasis, Bladder Cancer
Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
For patients who have one or two metastases in the brain, the tumor(s) can often be removed with surgery to relieve symptoms from the tumor(s) and to improve survival.
- Conditions
- Brain Metastasis, Bladder Cancer, Breast Cancer, Cervical Cancer
- Trial name
- NCT00587964
- Testing
- Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Carcinoma, Non-Small-Cell Lung, Urinary Bladder Neoplasms
Clinical Study of Microdosing Carboplatin in Lung or Bladder Cancer
Carboplatin kills cancer cells mainly through induction of DNA damage (drug-DNA adducts). The goal of this clinical trial is to determine if chemoresistance to carboplatin can be identified by measuring carboplatin-induced DNA…
- Trial name
- NCT01261299
- Testing
- Carbon-14-labeled carboplatin
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- University of California, Davis
Hepatopancreaticobiliary (HPB) Malignancy, Gall Bladder Cancer
Outcomes and Prognostic Factors in Hepatopancreatoduodenectomy
1. In biliary tract malignancies, achieving a microscopically clear resection margin (R0) is considered the only treatment for a cure. 2.
- Conditions
- Hepatopancreaticobiliary (HPB) Malignancy, Gall Bladder Cancer, Bile Duct Cancer, Pancreatoduodenectomy
- Trial name
- HPD_single (NCT06631352)
- Testing
- Hepatopancreatoduodenectomy
- Volunteers
- 50 people
- Sponsor
- Seoul National University Hospital
High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable: a Multi-center Study
This is a phase II study to determine the safety and efficacy of tislelizumab when given in combination with nab-paclitaxel as treatment for patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC) which is not…
- Trial name
- NCT05418309
- Testing
- Tislelizumab Nab paclitaxel
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Tianjin Medical University Second Hospital
Bladder Cancer
Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer
To combine oxaliplatin and taxotere in patients who have had prior cisplatin therapy in bladder cancer.
- Trial name
- NCT00186277
- Testing
- Oxaliplatin, Taxotere
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Stanford University
Metastatic Urothelial Carcinoma, Platinum-Resistant Urothelial Carcinoma
Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer
This phase II trial compares the effect of adding radiation therapy to an immunotherapy drug called pembrolizumab versus pembrolizumab alone in treating patients with urothelial cancer that has spread from where it first started…
- Conditions
- Metastatic Urothelial Carcinoma, Platinum-Resistant Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8
- Trial name
- NCT04936230
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- 83 sites in United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer
Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
This is a single-arm, multicenter study to evaluate the efficacy and safety of HX008 injection in patients with BCG-unresponsive non-muscle invasive bladder cancer.
- Trial name
- NCT04738630
- Testing
- HX008
- Where
- 5 sites in China
- Volunteers
- 110 people
- Sponsor
- Taizhou Hanzhong biomedical co. LTD
Recurrent Bladder Cancer, Stage IV Bladder Cancer
Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma
A multicenter, randomized, Phase 2 trial to study the effectiveness and feasibility of association of trastuzumab with combination chemotherapy in advanced or metastatic bladder cancer patients.
- Conditions
- Recurrent Bladder Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder
- Trial name
- CVH-CT02 (NCT01828736)
- Testing
- Trastuzumab, Gemcitabine, Carboplatin
- Where
- 15 sites in Belgium, France
- Volunteers
- 61 people
- Sponsor
- Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Bladder Cancer
First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC
The purpose of this study is to compare the safety and efficacy of EN3348 (MCC) versus BCG as first line treatment in patients with non-muscle invasive bladder cancer that are at high risk for recurrence or progression.
- Trial name
- NCT01284205
- Testing
- Mycobacterial Cell-Wall DNA Complex, Bacillus Calmette-Guerin
- Where
- 14 sites in United States
- Sponsor
- Bioniche Life Sciences Inc.
Recurrent Colon Cancer, Recurrent Rectal Cancer
2 Phase Comparison of Pre-operative CT and PET Images for Metastatic Colorectal Cancer
This pilot phase II studies how well computed tomography (CT) and positron emission tomography (PET) imaging works in detecting disease in patients undergoing surgery for metastatic colorectal cancer.
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV A Bladder Cancer, Stage IV A Rectal Cancer
- Trial name
- NCT01821105
- Testing
- PET Scan, CT Scan, fludeoxyglucose F 18
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Bladder Cancer
Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab
monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2; Recent phase I trial provided evidence of activity of pembrolizumab in advanced…
- Trial name
- PANDORE (NCT03212651)
- Testing
- Pembrolizumab
- Where
- France
- Volunteers
- 41 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
MIBC, mpMRI
Early Prediction of Neoadjuvant Chemotherapy Response in Bladder Cancer Using Quantitative Multiparametric MRI
Bladder cancer is a prevalent malignancy globally, with muscle-invasive disease having a five-year survival rate below 50%. Neoadjuvant chemotherapy (NAC) before radical cystectomy has shown efficacy for resectable…
- Conditions
- MIBC, mpMRI, NAC
- Trial name
- mpMRI (NCT07202845)
- Testing
- Multiparametric Magnetic Resonance Imaging (mpMRI)
- Where
- Egypt
- Volunteers
- 39 people
- Sponsor
- Assiut University
Bladder Cancer
Sorafenib and Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent
Safety profile and to determine maximum tolerated dose of Sorafenib in combination with Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent
- Trial name
- SOGUG-07-01 (NCT00544609)
- Testing
- Sorafenib, Radiotherapy
- Where
- 3 sites in Spain
- Volunteers
- 10 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Non-Muscle-Invasive Bladder Cancer
HIVEC in Patients With Non-Muscle-Invasive Bladder Cancer
The purpose of this study is to determine the efficacy and safety of Hyperthermic Intravesical Chemotherapy (HIVEC) with Gemcitabine (GEM) after Transurethral Resection of Bladder Tumors (TURBT) in the treatment of medium or…
- Trial name
- NCT06327932
- Testing
- TURBT, HIVEC, Intravesical Chemotherapy
- Volunteers
- 320 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Urinary Bladder Cancer
Clinicoepidimiological Study and Clinical Outcome in Patients With Urinary Bladder Cancer
To pinpoint the clinical ,epidimiological factors and clinical outcomes in urinary bladder cancer patients attending to our department during 5 years period between 2015-2019.
- Trial name
- NCT04525781
- Volunteers
- 150 people
- Sponsor
- Assiut University
Bladder Cancer, Pancreas Cancer
A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors
This multicenter, non-randomized, Phase II study will assess the efficacy, safety, and pharmacokinetics of trastuzumab emtansine in participants with HER2 overexpressing locally advanced (unresectable and not treatable with…
- Conditions
- Bladder Cancer, Pancreas Cancer, Cholangiocellular Carcinoma
- Trial name
- KAMELEON (NCT02999672)
- Testing
- Trastuzumab Emtansine
- Where
- 16 sites in Italy, Netherlands and 2 more
- Volunteers
- 20 people
- Sponsor
- Hoffmann-La Roche
Efficacy of Peripheral Nerve Blocks on Complications, Morbidity and Mortality
Retrospective Evaluation of the Effect of Ultrasound-guided Obturator Nerve Block on Complications in Transurethral (TUR-M) Resection Surgery for Bladder Side Wall Tumors.
In this study, the effectiveness of obturator nerve block added to spinal anesthesia in the operation of transurethral resection (TUR-M) of bladder lateral-infrolateral wall tumors on the obturator reflex and related…
- Trial name
- NCT04995445
- Where
- Turkey (Türkiye)
- Volunteers
- 115 people
- Sponsor
- Erol Olcok Corum Training and Research Hospital
Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8
Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer
This phase II trial tests whether sacituzumab govitecan given before radical cystectomy works in treating patients with non-urothelial bladder cancer.
- Conditions
- Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
- Trial name
- NCT05581589
- Testing
- Lymphadenectomy, Radical Cystectomy, Sacituzumab Govitecan
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Washington
Metastatic Urothelial Carcinoma, Bladder Cancer
Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma
This research study is examining the effectiveness of pembrolizumab plus cryoablation or aveluma plus cryoablation on people with urothelial carcinoma, including bladder cancer, that has spread.
- Trial name
- NCT04701918
- Testing
- Pembrolizumab, Cryoablation, Avelumab
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Massachusetts General Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.